The company beat analysts' average estimates on the top and bottom lines and guided to $7.3 billion to $7.4 billion in revenues for fiscal 2026.
With the permit, St. Louis-based C2N can offer its PrecivityAD2 and PrecivityAD Alzheimer's blood tests to patients in New York State.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback